AST-3424

N/A

Report date: 2025/09/25 17:04:46
NMEFirst In Class

Base Information

Drug NameAST-3424
Drug Alias NameTH-3424OBI-3424AST-006AST-3424HSE-001
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAldo-keto-reductase family 1 member C3 substratesAlkylating agents
TargetsAldo-keto-reductase family 1 member C3DNA
Therapy Area/IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[19] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesThreshold Pharmaceuticals
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesNational Cancer InstituteZhejiang Hisun Pharmaceutical Co LtdAscentawits Pharmaceuticals Ltd
Inactive CompaniesObi Pharma Inc
Active IndicationsSolid tumoursMyelodysplastic SyndromesUrinary Bladder Neoplasms +[17] 
Inactive IndicationsPancreatic NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A